Oral Kaposi's sarcoma in acquired immunodeficiency syndrome. Review of management and report of the efficacy of intralesional vinblastine

Cancer. 1989 Dec 15;64(12):2424-30. doi: 10.1002/1097-0142(19891215)64:12<2424::aid-cncr2820641205>3.0.co;2-x.

Abstract

Treatment of palatal Kaposi's sarcoma (KS) with intralesional injection of vinblastine was seen to provide effective palliation. Of the ten patients studied, four had a 25% to 50% response, two 50% to 75% response, and four had 75% to 100% response with one or two intralesional injections of vinblastine. Response to treatment was followed for a mean of 3.6 months, with recurrence of lesions in two of ten patients.

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications*
  • Adult
  • Humans
  • Injections, Intralesional
  • Male
  • Middle Aged
  • Mouth Neoplasms / drug therapy*
  • Mouth Neoplasms / pathology
  • Palatal Neoplasms / drug therapy*
  • Palatal Neoplasms / pathology
  • Sarcoma, Kaposi / drug therapy*
  • Sarcoma, Kaposi / pathology
  • Vinblastine / administration & dosage
  • Vinblastine / therapeutic use*

Substances

  • Vinblastine